期刊
MOLECULAR SYSTEMS BIOLOGY
卷 14, 期 5, 页码 -出版社
WILEY
DOI: 10.15252/msb.20177998
关键词
connectivity map; drug discovery; pathways; sepsis
资金
- NIH [ES00002, 5T32HL007118]
- DARPA [W911NF-10-1-0217]
- CIRCUITS grant from the Cure Alzheimer's Fund
- Joseph D. Brain Fellowship Fund
- Jere Meade Fellowship Fund
- National Institute for Health Research (NIHR) Sheffield Biomedical Research Centre (Translational Neuroscience)/NIHR Sheffield Clinical Research Facility
Attempts to develop drugs that address sepsis based on leads developed in animal models have failed. We sought to identify leads based on human data by exploiting a natural experiment: the relative resistance of children to mortality from severe infections and sepsis. Using public datasets, we identified key differences in pathway activity (Pathprint) in blood transcriptome profiles of septic adults and children. To find drugs that could promote beneficial (child) pathways or inhibit harmful (adult) ones, we built an in silico pathway drug network (PDN) using expression correlation between drug, disease, and pathway gene signatures across 58,475 microarrays. Specific pathway clusters from children or adults were assessed for correlation with drug-based signatures. Validation by literature curation and by direct testing in an endotoxemia model of murine sepsis of the most correlated drug candidates demonstrated that the Pathprint-PDN methodology is more effective at generating positive drug leads than gene-level methods (e.g., CMap). Pathway-centric Pathprint-PDN is a powerful new way to identify drug candidates for intervention against sepsis and provides direct insight into pathways that may determine survival.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据